Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Condition: Sarcoma Interventions: Drug: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]; Drug: Nivolumab IV Soln 100 MG/10ML; Drug: Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution Sponsor: Sarcoma Oncology Research Center, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials